Last $13.49 USD
Change Today -0.41 / -2.95%
Volume 870.8K
SRPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (SRPT) Snapshot

Open
$13.84
Previous Close
$13.90
Day High
$14.09
Day Low
$13.23
52 Week High
04/21/14 - $40.00
52 Week Low
01/14/15 - $11.33
Market Cap
557.3M
Average Volume 10 Days
1.2M
EPS TTM
$-3.39
Shares Outstanding
41.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAREPTA THERAPEUTICS INC (SRPT)

sarepta therapeutics inc (SRPT) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

204 Employees
Last Reported Date: 02/26/15
Founded in 1980

sarepta therapeutics inc (SRPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $457.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $377.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $376.9K
Senior Vice President of Technical Operations
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

sarepta therapeutics inc (SRPT) Key Developments

Sarepta Therapeutics, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Sarepta Therapeutics, Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Sarepta reported revenue from research contracts and other grants of $0.03 million against $2.6 million last year. Operating loss was $44.7 million against $32.8 million last year. Net loss was $44.4 million or $1.08 per basic and diluted share against $8.8 million or $0.23 per basic and diluted share last year. Non-GAAP net loss was $38.6 million, or $0.94 per basic and diluted share, compared to non-GAAP net loss of $29.1 million or $0.77 per basic and diluted share last year. The incremental loss of $9.5 million was primarily the result of increased operating expenses as well as a decrease in revenue from the company’s government contracts. The increase in net loss is primarily the result of a $24.0 million decrease in gain on change in warrant valuation, an increase of $9.3 million in operating expenses as a result of corporate growth and a decrease of $2.6 million in revenue from the company’s government contracts. Revenue for the fourth quarter of 2014 decreased by $2.6 million primarily due to the July 2014 expiration of the Marburg portion of the company’s Ebola-Marburg U.S. government contract. For the year, Sarepta reported revenue from research contracts and other grants of $9.8 million against $14.2 million last year. Operating loss was $133.8 million against $90.3 million last year. Net loss was $135.8 million or $3.39 per basic and diluted share against $112 million or $3.31 per basic and diluted share last year. The $43.5 million increase in operating loss was the result of a $21.3 million increase in research and development expenses and a $17.7 million increase in general and administrative expenses as well as a $4.5 million decrease in revenue from the company’s government contracts. Revenue for the year ended December 31, 2014 decreased primarily due to the July 2014 expiration of the Marburg portion of the company’s Ebola-Marburg U.S. government contract. Non-GAAP net loss was $112.7 million, or $2.81 per basic and diluted share, compared to non-GAAP net loss of $78.1 million or $2.31 per basic and diluted share last year.

Sarepta Therapeutics, Inc. to Report Q4, 2014 Results on Feb 26, 2015

Sarepta Therapeutics, Inc. announced that they will report Q4, 2014 results at 8:00 AM, US Eastern Standard Time on Feb 26, 2015

Sarepta Therapeutics, Inc., Q4 2014 Earnings Call, Feb 26, 2015

Sarepta Therapeutics, Inc., Q4 2014 Earnings Call, Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRPT:US $13.49 USD -0.41

SRPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,476 GBp +6.00
Baxter International Inc $69.96 USD +0.81
Gilead Sciences Inc $103.83 USD +0.30
Hemispherx Biopharma Inc $0.25 USD +0.007
SciClone Pharmaceuticals Inc $7.79 USD +0.08
View Industry Companies
 

Industry Analysis

SRPT

Industry Average

Valuation SRPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 58.8x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 36.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit www.sareptatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.